相关临床试验
0
0 进行中
药物批准
9
批准总数
监管机构
2
监管机构数
成立时间
2018
暂无试验阶段数据
暂无试验数据
暂无试验数据
- The global Claudin 18.2 targeted therapy market is projected to exceed $800 million by 2030, driven by significant opportunities in treating advanced gastric and pancreatic cancers. - Currently one approved therapy exists with over 70 Claudin 18.2 targeted therapies in clinical trials across various development stages, spanning monoclonal antibodies, bispecific antibodies, and CAR-T cell therapies. - Astellas' zolbetuximab (Vyloy) leads the field as the first approved Claudin 18.2 targeted therapy, showing promising results in advanced gastric cancer treatment. - Future expansion is expected beyond gastric cancer into pancreatic, colorectal, and esophageal cancers, with personalized medicine approaches based on individual genetic profiles.
- Compass Therapeutics appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, both effective January 1, 2026. - Prasad brings extensive commercial experience including over 10 successful oncology launches, notably the blockbuster VORANIGO launch in 2024 and TIBSOVO for biliary tract cancer patients. - Sirard contributes more than two decades of oncology drug development expertise, having guided multiple programs through clinical development, pivotal trials, and regulatory approval. - The appointments strengthen Compass's execution capabilities as the company advances tovecimig and its broader immuno-oncology pipeline toward potential commercialization.
- Extended follow-up data from the phase 3 INDIGO trial confirms vorasidenib's durable treatment benefit, with median progression-free survival not estimable versus 11.4 months for placebo. - The targeted therapy significantly reduced tumor growth rate and seizure frequency compared to placebo, with only 32% of vorasidenib patients experiencing disease progression versus 64% on placebo. - Safety profile remained manageable with fewer than 5% of patients discontinuing treatment due to adverse events and no treatment-related deaths reported. - These results strengthen the clinical evidence supporting vorasidenib as the first FDA-approved targeted therapy for grade 2 IDH-mutant glioma following surgical resection.
- Black Diamond Therapeutics has completed enrollment in its mid-stage study of silevertinib, a fourth-generation EGFR inhibitor targeting non-classical EGFR mutations in frontline NSCLC patients. - The company plans to disclose objective response rate and duration of response data from all 43 patients in Q4 2025, with FDA feedback on a potential registrational path expected in H1 2026. - Silevertinib faces significant competition in the NSCLC space, particularly from Johnson & Johnson's recently approved Rybrevant plus Lazcluze combination and AstraZeneca's established Tagrisso therapy. - Following the outlicensing of BDTX-4933 to Servier Pharmaceuticals, Black Diamond is now solely focused on silevertinib development and actively seeking strategic partners for advancement.
- The FDA approved Voranigo (vorasidenib) on August 6, 2024, as the first targeted treatment for Grade 2 IDH-mutant astrocytoma or oligodendroglioma in patients 12 years and older. - Phase 3 INDIGO trial results showed Voranigo significantly extended progression-free survival to 27.7 months compared to 11.1 months with placebo. - The drug works by blocking mutant IDH1 and IDH2 enzymes, reducing tumor activity and crossing the blood-brain barrier to effectively treat brain tumors. - Common side effects include tiredness (37%), COVID-19 (33%), and muscle or joint pain (26%), with liver function monitoring required during treatment.
• The FDA is considering removing oral phenylephrine from its OTC Monograph due to a lack of efficacy as a nasal decongestant, potentially impacting numerous cold and allergy products. • Novartis' Scemblix expands its FDA-approved uses to include the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ PML). • Astellas Pharma's Vyloy (zolbetuximab) receives FDA approval as the first treatment targeting the CLDN18.2 protein for gastric or gastroesophageal junction adenocarcinoma. • Iterum Therapeutics' Orlynvah (sulopenem) gains FDA approval for treating uncomplicated urinary tract infections in women with limited oral antibacterial treatment options.
- The FDA has approved the Ion Torrent Oncomine Dx Target Test as a companion diagnostic for vorasidenib in grade 2 astrocytoma or oligodendroglioma. - Vorasidenib is the first targeted therapy for patients with grade 2 IDH-mutant glioma, offering a new treatment option after nearly 25 years. - The Oncomine Dx Target Test simultaneously delivers biomarker results for multiple therapies from a single sample, quickly matching patients to treatments. - Vorasidenib demonstrated a 61% reduction in disease progression or death risk compared to placebo in the phase 3 INDIGO trial.
• The FDA has approved vorasidenib (Voranigo) as a systemic therapy for Grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. • Vorasidenib, developed by Servier Pharmaceuticals, targets the mutant IDH protein, reducing tumor size and delaying the need for other interventions like radiation or chemotherapy. • Clinical trials, including those at Duke University, showed that patients on vorasidenib experienced extended periods without tumor progression. • The approval marks a significant advancement, offering a targeted oral treatment that allows patients to maintain their quality of life during treatment.
- Leading pharmaceutical companies including GSK, Schrödinger, and Insilico Medicine showcase how AI and machine learning are transforming the drug discovery process, with potential to create a $50 billion market in the next decade. - Advanced AI platforms like Schrödinger's Autodesigner demonstrate remarkable efficiency, generating 118,000 drug candidate ideas in one day compared to 317 ideas from traditional crowdsourcing methods over two weeks. - Companies are leveraging AI across multiple areas including target discovery, molecular design, and clinical trial simulation, with Insilico Medicine expanding to over 30 drug development programs in just four years.
- Vorasidenib, the first targeted therapy developed specifically for brain cancer, more than doubled progression-free survival in patients with recurrent grade 2 glioma carrying IDH1/IDH2 mutations, extending the time without disease progression from 11.1 months to 27.7 months. - The international INDIGO trial involving 331 patients demonstrated that vorasidenib delayed the need for chemotherapy and radiation by nearly 17 months compared to placebo, with 85.6% of patients going 18 months before requiring next treatment. - The drug showed excellent tolerability with limited adverse effects, offering a new treatment option for younger patients typically in their 30s and 40s who face cognitive deficits from standard radiation and chemotherapy treatments. - Results from this phase 3 study, published in the New England Journal of Medicine and presented at ASCO, are expected to establish a new standard of care for IDH-mutant low-grade gliomas pending FDA approval.
